Literature DB >> 20646335

Updating the physiology, exploration and disease relevance of complement factor H.

V Buhé, S Loisel, J O Pers, K Le Ster, C Berthou, P Youinou.   

Abstract

The factor H (FH) protein (also known as beta1H globulin) is the main regulator of the complement alternative pathway. It exhibits multivalent binding sites to the complement component C3b, and polyanions and one binding site to sialic acid and cell surfaces. These multiple binding sites confer to FH a decay-accelerating factor activity in the fluid phase as well as at the cell surface. A defect in FH activity or a FH protein deficiency triggers chronic inflammation and tissue injury, leading to various disorders impacting the kidney or the eye. In contrast, some pathogens, as well as cancer cells, develop various strategies to bind FH and thereby subvert a complement attack. We focus on the functions of FH, and review the main pathological conditions in which FH is involved. Since the pathogenesis is elusive, appropriate FH dosage in biological fluids and FH gene analysis may help in improving understanding of such diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20646335     DOI: 10.1177/039463201002300202

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  2 in total

1.  c-Jun and c-Fos regulate the complement factor H promoter in murine astrocytes.

Authors:  Laura A Fraczek; Carol B Martin; Brian K Martin
Journal:  Mol Immunol       Date:  2011-09-14       Impact factor: 4.407

Review 2.  Regulation of the metastatic cell phenotype by sialylated glycans.

Authors:  Matthew J Schultz; Amanda F Swindall; Susan L Bellis
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.